EMA Recommends Extension of Indications for Inotuzumab Ozogamicin By Ogkologos - April 29, 2026 126 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns treatment of paediatric patients with CD22-positive B cell precursor ALL Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR The First Report from the Cancer Programme of the 100,000 Genomes... January 16, 2024 Health inequalities: “We have a moral duty to reduce them” February 15, 2022 Sodium Thiosulfate Prevents Cisplatin-Induced Hearing Loss in Some Children July 13, 2018 Off Target: Investigating the Abscopal Effect as a Treatment for Cancer January 28, 2020 Load more HOT NEWS Virtual Mind–Body Fitness Classes Show Unexpected Benefit in People with Cancer ESMO Congress 2023, 20-24 October 2023 Madrid, Spain Weak Immunogenicity in Patients with Cancer After First Dose of mRNA-based... FDA Approves Melphalan As a Liver-Directed Treatment for Uveal Melanoma
